





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(Use as many sheets as necessary)*

Sheet

1

of

2

*Complete if Known*

Application Number	10/698,924
Filing Date	October 31, 2003
First Named Inventor	K. Raja Reddy
Art Unit	1626
Examiner Name	Taofiq A. Solola
Attorney Docket Number	2358.0180003/RWE/AES

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T <sup>2</sup>
Y0	NPL1	BRAESS, J. et al. "Oral Cytarabine Ocfosfate in Acute Myeloid Leukemia and non-Hodgkin's Lymphoma – Phase I/II Studies and Pharmacokinetics", <i>Leukemia</i> 12:1618-1626, Stockton Press (1998)	
	NPL2	CHABNER, B.A., "Cytidine Analogues", in <i>Cancer Chemotherapy: Principles and Practice</i> , Lippincott Williams & Wilkins (1990)	
	NPL3	CHABNER, B.A., et al., "Purification and Properties of Cytidine Deaminase from Normal and Leukemic Granulocytes", <i>Journal of Clinical Investigation</i> 53:922-931, American Society for Clinical Investigation (1974)	
	NPL4	COHEN, S.S. "The Mechanisms of Lethal Action of Arabinosyl Cytosine (araC) and Arabinosyl Adenine (araA)", <i>Cancer</i> 40:509-518, Wiley (1977)	
	NPL5	GRANT, S., "Biochemical Modulation of Cytosine Arabinoside", <i>Pharmac. Ther.</i> 48:29-44, Pergamon Press plc (1990)	
	NPL6	LEACH, W.B. et al. "Toxicity Studies in Mice Treated with 1-β-D-Arabinofuranosyl-cytosine (ara-C)", <i>Cancer Research</i> 29:529-535, American Association for Cancer Research (1969)	
	NPL7	PLUNKETT, W. et al. "Pharmacologically Directed Ara-C Therapy for Refractory Leukemia", <i>Seminars in Oncology</i> 12(2) Supp. 3:20-30, W.B. Saunders (1985)	
	NPL8	RUSTUM, Y.M., et al. "1-β-Arabinofuranosylcytosine in Therapy of Leukemia: Preclinical and Clinical Overview" <i>Pharmac. Ther.</i> 56:307-321, Pergamon Press Ltd. (1992)	
	NPL9	SARTILLO-PISCIL, F., et al., "Fosfato-ésteres cílicos diastereoisoméricos: 5-bromo-4-fenil-2-fenoxy-2-oxo-1,3,2-dioxafosforinanos, precursores de radicales libres alquilo β-fosfatoxi y generadores de radicales cationicos en medio no oxidativo," <i>Rev. Soc. Quim. Mexico</i> 46:330-334, Journal of the Mexican Chemical Society (December 2002)	Yes
	NPL10	English Translation of SARTILLO-PISCIL, F., et al., "Cyclic diastereoisomeric phosphate esters: 5-bromo-4-phenyl-2-phenoxy-2-oxo-1,3,2-dioxaphosphorinanes, free β-(phosphatoxy) alkyl radical precursors and cation radical generators in non-oxidative medium," <i>Rev. Soc. Quim. Mexico</i> 46:330-334, Journal of the Mexican Chemical Society (December 2002)	

Examiner Signature	T. A. Solola	Date Considered	6-14-06
--------------------	--------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**THIRD SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(Use as many sheets as necessary)*

Sheet 2 of 2

**Complete if Known**

Application Number 10/698,924

Filing Date October 31, 2003

First Named Inventor K. Raja Reddy

Art Unit 1626

Examiner Name Taofiq A. Solola

Attorney Docket Number 2358.0180003/RWE/AES

Y0	NPL11	SHIMMA, N. et al., "The Design and Synthesis of a New Tumor-Selective Fluoropyrimidine Carbamate, Capecitabine" <i>Bioorganic &amp; Medicinal Chemistry</i> 8:1697-1706, Elsevier Science Ltd. (2000)	
	NPL12	SUTO, T. et al. "The Effect of YNK-01 (an Oral Prodrug of Cytarabine) on Hepatocellular Carcinoma" <i>Seminars in Oncology</i> 24(2) Suppl 6:S6-122-S6-129, W.B. Saunders (1997)	
	NPL13	TAKAKU, H., et al., "Synthesis of Deoxyribooligonucleotides Using Cesium Fluoride by the Phosphotriester Approach," <i>Nippon Kagaku Kaishi</i> (no. 10):1968-1973, The Chemical Society of Japan, Inc. (1985)	Yes
	NPL14	English translation of TAKAKU, H., et al., "Synthesis of Deoxyribooligonucleotides Using Cesium Fluoride by the Phosphotriester Approach," <i>Nippon Kagaku Kaishi</i> (no. 10):1968-1973, The Chemical Society of Japan, Inc. (1985)	
	NPL15	THUONG, N.-T. and Chabrier, P., "Nouvelle méthode de préparation de la phosphorylcholine, de la phosphorylhomocholine et de leurs dérivés," <i>Bull. Soc. Chim. France</i> 1-2:667-671, Masson and Co. (1974)	Yes
	NPL16	English translation of THUONG, N.T. and Chabrier, P., "New Method for Preparation of Phosphoryl choline, of phosphoryl homocholine and their derivatives," <i>Bull. Soc. Chim. France</i> 1-2:667-671, Masson and Co. (1974)	
	NPL17	YOSHIDA, Y. et al., "Participation of the Peroxisomal $\beta$ -Oxidation System in the Chain-Shortening of PCA <sub>16</sub> , A Metabolite of the Cytosine Arabinoside Prodrug, YNK01, in Rat Liver" <i>Biochemical Pharmacology</i> 39(10):1505-1512, Pergamon Press plc (1990)	
	NPL18	Dialog File 351, Accession No. 11683821, WPI English language abstract of WO 97/49717 (Document FP3 listed on accompanying PTO/SB/08A form)	12/31/97
↓	NPL19	Copy of Office Action for United States Patent Application No. 10/698,928, Boyer et al., mailed March 13, 2006	

525261\_1.DOC

Examiner Signature	T. A. Solola	Date Considered	6-14-06
--------------------	--------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.